Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (4): 758-761. doi: 10.19723/j.issn.1671-167X.2023.04.031

Previous Articles     Next Articles

Globular placenta with infarction: A case report

Tai-yang LI,Yan ZHANG*()   

  1. Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China
  • Received:2020-08-31 Online:2023-08-18 Published:2023-08-03
  • Contact: Yan ZHANG E-mail:zhangyann01@126.com

Abstract:

Globular placenta is a rare type of abnormal placental morphology. It shows small placental volume and placental thickening on imaging, and the placental edge is round and blunt. Some studies have pointed out that it may be due to the invasion of superficial villi into maternal tissue and insufficient transformation of spiral arterioles. It leads to placental ischemia, and early poor perfusion causes abnormal placenta morphology, which is manifested as fibrin deposition around the villi under the microscope. Because the effective exchange area of the globular placenta is smaller than that of the normal placenta, its influence on the fetus gradually appears with the increase of gestational age. Studies have observed that placental volume and placental thickness are associated with fetal growth restriction during pregnancy. Growth-restricted fetuses are at increased risk for perinatal diseases such as intraventricular hemorrhage, periventricular leukomalacia, respiratory distress syndrome, necrotizing enterocolitis, etc. Hemodynamic parameters will reflect the problem of placental perfusion, such as the peak systolic/diastolic blood flow of the uterine artery and umbilical artery, etc. During pregnancy, these two ultrasound indicators and placental morphology should be monitored to detect the disease at an early stage and in the early stage of disease progression. The use of drug intervention may improve perinatal outcomes, but the current clinical evidence is insufficient. Most physicians use empirical treatment, that is, to improve placental circulation and increase perfusion, but there is currently no obvious effective drug. There is no consensus on the doses of drugs such as aspirin and heparin, and the reported obstetric outcomes vary from study to study. In order to better treat these diseases, provide more adequate clinical data, and lay the foundation for further research in the later period, this report describes a young woman who was treated in our hospital. This report describes a young woman who presented to our hospital with a thickening of the placenta on mid-trimester ultrasonography, aggressive use of drug therapy and close follow-up when the fetus did not lag behind, and who developed fetal lag in the third trimester and was accompanied by The fetus was hemodynamically abnormal, and a live birth was obtained after timely termination of the pregnancy, but early necrotizing enteritis developed. Finally, we combined the literature review to understand the pathological mechanism, clinical characteristics, disease prognosis and corresponding treatment methods of the disease.

Key words: Globular placenta, Placenta floor infarction, Fetal growth restriction

CLC Number: 

  • R714.4

Table 1

Ultrasound parameters of each gestational age"

Item 15+2 22+0 25+0 30+0 32+2 33+1 33+4
Length/cm 8.2 10.7 - 10.9 13.2 13.2 -
Width/cm 8.0 - - 11.1 11.7 11.4 -
Thickness/cm 4.8 5.3 6.0 7.7 7.0 7.6 7.0
Umbilical artery S/D* - - - 1.92 3.1-3.9 4.1-5.4 3.11-3.87
Amniotic fluid index/cm 3.3? 5.3? 4.8? 14.1 10.1 11.6 10.6
Ultrasound gestational age /(weeks+ days) - 21+2 24+1 29+2 31+5 - 32+0

Figure 1

Ultrasound image of the placenta length(A)and the thickest part(B)in the third trimester"

Figure 2

Ultrasound flow spectrum of proximal (A) and distal (B) umbilical arteries in the third trimester"

Figure 3

Fetus-facing placental appearance"

Figure 4

Side view of placenta"

Figure 5

Fetus-facing placental appearance"

1 Masliza WDW , Daud W , Bajuri MY , et al. Sonographically abnormal placenta: An association with an increased risk poor pregnancy outcomes[J]. Clin Ter, 2017, 168 (5): 283- 289.
2 Quant HS , Sammel MD , Parry S , et al. Second-trimester 3-dimensional placental sonography as a predictor of small-for-gestational-age birth weight[J]. J Ultrasound Med, 2016, 35 (8): 1693- 1702.
doi: 10.7863/ultra.15.06077
3 Fisteag-Kiprono L , Neiger R , Sonek JD , et al. Perinatal outcome associated with sonographically detected globular placenta[J]. J Reprod Med, 2006, 51 (7): 563- 566.
4 王萍. 胎盘增厚168例临床分析[D]. 福州: 福建医科大学, 2017.
5 唐志会, 王刚, 郝玉娟. 胎儿生长受限的胎盘MRI表现特点分析[J]. 中国CT和MRI杂志, 2019, 17 (6): 104- 107.
6 Figueras F , Gratacos E . Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol[J]. Fetal Diagn Ther, 2014, 36 (2): 86- 98.
doi: 10.1159/000357592
7 Damodaram M , Story L , Eixarch E , et al. Placental MRI in intrauterine fetal growth restriction[J]. Placenta, 2010, 31 (6): 491- 498.
doi: 10.1016/j.placenta.2010.03.001
8 阮焱, 王欣. 320例胎儿生长受限临床分析[J]. 医学综述, 2015, 21 (7): 1287- 1289.
doi: 10.3969/j.issn.1006-2084.2015.07.053
9 Al-Sahan N , Grynspan D , von Dadelszen P , et al. Maternal floor infarction: management of an underrecognized pathology[J]. J Obstet Gynaecol Res, 2014, 40 (1): 293- 296.
doi: 10.1111/jog.12159
10 Hansen AT , Sandager P , Ramsing M , et al. Tinzaparin for the treatment of fetal growth retardation: An open-labelled randomized clinical trial[J]. Thromb Res, 2018, 170, 38- 44.
doi: 10.1016/j.thromres.2018.08.006
11 陈永利. 阿斯匹林联合低分子肝素治疗胎儿生长受限的临床疗效及对胎儿血流参数变化母婴结局的影响[J]. 河北医学, 2019, 25 (3): 691- 695.
doi: 10.3969/j.issn.1006-6233.2019.03.043
[1] ZENG Hong, WANG Yan, WANG Yang, GUO Xiang-yang. Perioperative management of abdominal aortic balloon occlusion in patients complicated with placenta percteta: a case report [J]. Journal of Peking University(Health Sciences), 2015, 47(6): 1031-1033.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 443 -444 .
[2] . [J]. Journal of Peking University(Health Sciences), 2001, 33(6): 532 -535 .
[3] . [J]. Journal of Peking University(Health Sciences), 2001, 33(1): 73 -75 .
[4] . [J]. Journal of Peking University(Health Sciences), 2001, 33(1): 16 .
[5] . [J]. Journal of Peking University(Health Sciences), 2001, 33(2): 144 -146 .
[6] . [J]. Journal of Peking University(Health Sciences), 2001, 33(6): 548 -551 .
[7] . [J]. Journal of Peking University(Health Sciences), 2001, 33(3): 258 -262 .
[8] . [J]. Journal of Peking University(Health Sciences), 2001, 33(4): 321 -315 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(6): 562 -564 .
[10] . [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 112 -115 .